Treats hypertension. ANDA 214608, held by Granules. Prazosin Hydrochloride.
As of Nov 16, 2026, ANDA 214608 (Prazosin Hydrochloride), held by Granules, was first approved by FDA on Dec 23, 2021, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Prazosin hydrochloride capsules, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 23, 2021 | Original application | Approved | None posted |
| Prazosin HydrochlorideEQ 1MG BASE · capsule;oral | Prazosin Hydrochloride | Rx |
| Prazosin HydrochlorideEQ 2MG BASE · capsule;oral | Prazosin Hydrochloride | Rx |
| Prazosin HydrochlorideEQ 5MG BASE · capsule;oral | Prazosin Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters